US EditionPublished • loading... • Updated
Merck & Co. Touts $6.7B Terns Deal, Highlights TERN-701 “Best-in-Class” CML Potential
Summary by watchlistnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Merck & Co. Touts $6.7B Terns Deal, Highlights TERN-701 “Best-in-Class” CML Potential
Merck & Co., Inc. (NYSE:MRK) held an investor event to discuss its planned acquisition of Terns Pharmaceuticals, emphasizing the strategic rationale, clinical data to date for Terns’ lead asset, and the financial terms of the deal. Deal rationale centers on TERN-701 and Merck’s hematology ambitions Chief Executive Officer Rob Davis said Merck’s “science-led strategy” includes […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
